TAVIST Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tavist, and when can generic versions of Tavist launch?
Tavist is a drug marketed by Novartis and Haleon Us Holdings and is included in four NDAs.
The generic ingredient in TAVIST is acetaminophen; clemastine fumarate; pseudoephedrine hydrochloride. There are sixty-six drug master file entries for this compound. Additional details are available on the acetaminophen; clemastine fumarate; pseudoephedrine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TAVIST?
- What are the global sales for TAVIST?
- What is Average Wholesale Price for TAVIST?
Summary for TAVIST
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 86 |
Clinical Trials: | 1 |
Patent Applications: | 3,376 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TAVIST at DailyMed |
![TAVIST drug patent expirations Drug patent expirations by year for TAVIST](/p/graph/s/t/TAVIST-patent-expirations.png)
Recent Clinical Trials for TAVIST
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of California, San Francisco | Phase 2 |
Moorfields Eye Hospital NHS Foundation Trust | Phase 2 |
US Patents and Regulatory Information for TAVIST
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | TAVIST | clemastine fumarate | SYRUP;ORAL | 018675-001 | Jun 28, 1985 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Haleon Us Holdings | TAVIST-1 | clemastine fumarate | TABLET;ORAL | 020925-001 | Aug 21, 1992 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Novartis | TAVIST | clemastine fumarate | TABLET;ORAL | 017661-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |